Potential promising of synthetic lethality in cancer research and treatment
Naunyn-Schmiedeberg's Archives of Pharmacology · 2025-02 · 398 (2) · 1403-1431
DOI: 10.1007/s00210-024-03444-6 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 21.09.2024. Verfasst von Mohsen Karami Fath und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cellular and Molecular Biology, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran. Hauptthemen laut MEDLINE: Neoplasms, Synthetic Lethal Mutations, Antineoplastic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 212 Literaturangaben.
Abstract (Originalsprache)
Cancer is a complex disease driven by multiple genetic changes, including mutations in oncogenes, tumor suppressor genes, DNA repair genes, and genes involved in cancer metabolism. Synthetic lethality (SL) is a promising approach in cancer research and treatment, where the simultaneous dysfunction of specific genes or pathways causes cell death. By targeting vulnerabilities created by these dysfunctions, SL therapies selectively kill cancer cells while sparing normal cells. SL therapies, such as PARP inhibitors, WEE1 inhibitors, ATR and ATM inhibitors, and DNA-PK inhibitors, offer a distinct approach to cancer treatment compared to conventional targeted therapies. Instead of directly inhibiting specific molecules or pathways, SL therapies exploit genetic or molecular vulnerabilities in cancer cells to induce selective cell death, offering benefits such as targeted therapy, enhanced treatment efficacy, and minimized harm to healthy tissues. SL therapies can be personalized based on each patient's unique genetic profile and combined with other treatment modalities to potentially achieve synergistic effects. They also broaden the effectiveness of treatment across different cancer types, potentially overcoming drug resistance and improving patient outcomes. This review offers an overview of the current understanding of SL mechanisms, advancements, and challenges, as well as the preclinical and clinical development of SL. It also discusses new directions and opportunities for utilizing SL in targeted therapy for anticancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cellular and Molecular Biology, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran.
- Pharmaceutical Sciences Research Center, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
- Molecular Medicine Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
- Department of Biotechnology, Faculty of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
- Faculty of Pharmacy, Zhengzhou University, Zhengzhou, China.
- Student Research Committee, Yasuj University of Medical Sciences, Yasuj, Iran.
Zitieren
APA
Karami Fath, M., Najafiyan, B., Morovatshoar, R., Khorsandi, M., Dashtizadeh, A., Kiani, A., Farzam, F., Kazemi, K. S., & Nabi Afjadi, M. (2025). Potential promising of synthetic lethality in cancer research and treatment. Naunyn-Schmiedeberg's Archives of Pharmacology, 398(2), 1403-1431. https://doi.org/10.1007/s00210-024-03444-6
Vancouver
Karami Fath M, Najafiyan B, Morovatshoar R, Khorsandi M, Dashtizadeh A, Kiani A, et al. Potential promising of synthetic lethality in cancer research and treatment. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025;398(2):1403-1431. doi:10.1007/s00210-024-03444-6
BibTeX
@article{KaramiFath2025,
author = {Karami Fath, Mohsen and Najafiyan, Behnam and Morovatshoar, Reza and Khorsandi, Mahdieh and Dashtizadeh, Adib and Kiani, Arash and Farzam, Farnoosh and Kazemi, Kimia Sadat and Nabi Afjadi, Mohsen},
title = {Potential promising of synthetic lethality in cancer research and treatment},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2025},
volume = {398},
number = {2},
pages = {1403--1431},
doi = {10.1007/s00210-024-03444-6}
}
EUVIMED